Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABTECT-2

49 evidence topics · 9 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm in the posted results
PopulationABX464 50 mgABX464 25 mgPlaceboTotal
Started“318”“159”“159”Not reported
Baseline“318”“159”“159”“636”
Adverse events (at risk)“0/318 (0.00%)”“0/159 (0.00%)”“0/159 (0.00%)”Not reported
Description of analysis sets
Results
Participant disposition
Participant flow by arm in the posted results
DispositionABX464 50 mgABX464 25 mgPlacebo
Started“318”“159”“159”
Completed“291”“142”“145”
Not completed“27”“17”“14”
Adverse event“13”“8”“8”
Lack of efficacy“2”“2”“1”
Lost to follow-up“3”“0”“0”
Protocol violation“0”“1”“2”
Withdrawal by subject“9”“6”“3”
Baseline characteristics
Baseline characteristics by arm in the posted results
CharacteristicABX464 50 mg (n=318)ABX464 25 mg (n=159)Placebo (n=159)Total (n=636)
Age, years, mean (SD)“41.4(13.64)”“41.3(12.83)”“41.6(14.68)”“41.4(13.69)”
Age 65 years or older, participants“19”“6”“16”“41”
Female, participants“138”“60”“58”“256”
Male, participants“180”“99”“101”“380”
Asian, participants“66”“29”“39”“134”
Black or African American, participants“6”“3”“4”“13”
White, participants“231”“116”“108”“455”
Weight, kg, mean (SD)“71.75(17.101)”“73.37(16.050)”“73.91(17.387)”“72.69(16.919)”
Duration of ulcerative colitis, years, mean (SD)“7.74(7.193)”“7.92(6.769)”“7.75(6.503)”“7.79(6.911)”
At least one prior advanced therapy inadequate response, participants“159”“76”“79”“314”
Inadequate response to JAK inhibitors among those with AT-IR, participants“33”“19”“20”“72”
Modified Mayo Score, mean (SD)“6.9(1.11)”“7.0(1.04)”“6.8(0.98)”“6.9(1.06)”
Mayo endoscopic subscore 2, participants“130”“56”“64”“250”
Mayo endoscopic subscore 3, participants“188”“103”“95”“386”
Fecal calprotectin, µg/g, mean (SD)“3759.05(7548.48)”“4121.86(7081.92)”“4499.81(8074.99)”“4038.06(7569.95)”
Efficacy results
Primary and key secondary endpoints at Week 8
Endpoint at Week 8, % (n)Placebo (N=159)Obefazimod 25 mg (N=159)Obefazimod 50 mg (N=318)25 mg minus placebo, %25 mg p-value50 mg minus placebo, %50 mg p-value
Clinical remission (primary)“6.3 (10)”View highlighted excerpt for this quote“11.3 (18)”View highlighted excerpt for this quote“19.8 (63)”View highlighted excerpt for this quote“5.1”View highlighted excerpt for this quote“p = 0.1034”View highlighted excerpt for this quote“13.4”View highlighted excerpt for this quote“p = 0.0001”View highlighted excerpt for this quote
Clinical response“33.3 (53)”View highlighted excerpt for this quote“53.5 (85)”View highlighted excerpt for this quote“63.2 (201)”View highlighted excerpt for this quote“20.1”View highlighted excerpt for this quote“p = 0.0002”View highlighted excerpt for this quote“29.6”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Endoscopic improvement“10.1 (16)”View highlighted excerpt for this quote“22.0 (35)”View highlighted excerpt for this quote“35.5 (113)”View highlighted excerpt for this quote“12.0”View highlighted excerpt for this quote“p = 0.0029”View highlighted excerpt for this quote“25.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
HEMI“7.5 (12)”View highlighted excerpt for this quote“13.2 (21)”View highlighted excerpt for this quote“23.9 (76)”View highlighted excerpt for this quote“5.7”View highlighted excerpt for this quote“p = 0.0932”View highlighted excerpt for this quote“16.4”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Symptomatic remission“22.0 (35)”View highlighted excerpt for this quote“33.3 (53)”View highlighted excerpt for this quote“40.3 (128)”View highlighted excerpt for this quote“11.4”View highlighted excerpt for this quote“p = 0.0227”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote“p < 0.0001”View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Endpoint at Week 8, participantsABX464 50 mg (n=318)ABX464 25 mg (n=159)Placebo (n=159)
Clinical remission per modified Mayo Score (primary)“63”“18”“10”
Endoscopic improvement“113”“35”“16”
Clinical response per modified Mayo Score“201”“85”“53”
HEMI per Geboes“76”“21”“12”
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Endpoint at Week 8, % (n)AT-IR-Yes placebo (N=79)AT-IR-Yes 25 mg (N=76)AT-IR-Yes 50 mg (N=159)AT-IR-No placebo (N=80)AT-IR-No 25 mg (N=83)AT-IR-No 50 mg (N=159)
Clinical remission“5.1 (4)”View highlighted excerpt for this quote“5.3 (4)”View highlighted excerpt for this quote“12.6 (20)”View highlighted excerpt for this quote“7.5 (6)”View highlighted excerpt for this quote“16.9 (14)”View highlighted excerpt for this quote“27.0 (43)”View highlighted excerpt for this quote
Endoscopic improvement“8.9 (7)”View highlighted excerpt for this quote“11.8 (9)”View highlighted excerpt for this quote“26.4 (42)”View highlighted excerpt for this quote“11.3 (9)”View highlighted excerpt for this quote“31.3 (26)”View highlighted excerpt for this quote“44.7 (71)”View highlighted excerpt for this quote
Symptomatic remission“15.2 (12)”View highlighted excerpt for this quote“26.3 (20)”View highlighted excerpt for this quote“37.1 (59)”View highlighted excerpt for this quote“28.8 (23)”View highlighted excerpt for this quote“39.8 (33)”View highlighted excerpt for this quote“43.4 (69)”View highlighted excerpt for this quote
HEMI“6.3 (5)”View highlighted excerpt for this quote“7.9 (6)”View highlighted excerpt for this quote“17.0 (27)”View highlighted excerpt for this quote“8.8 (7)”View highlighted excerpt for this quote“18.1 (15)”View highlighted excerpt for this quote“30.8 (49)”View highlighted excerpt for this quote
Clinical response“20.3 (16)”View highlighted excerpt for this quote“40.8 (31)”View highlighted excerpt for this quote“57.2 (91)”View highlighted excerpt for this quote“46.3 (37)”View highlighted excerpt for this quote“65.1 (54)”View highlighted excerpt for this quote“69.2 (110)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events at Week 8 reported by the company
Event, n (%)Placebo (N=159)Obefazimod 25 mg (N=159)Obefazimod 50 mg (N=318)
Any TEAE“77 (48.4%)”“81 (50.9%)”“194 (61.0%)”
TEAE leading to study drug discontinuation“9 (5.7%)”“8 (5.0%)”“15 (4.7%)”
Serious TEAE“7 (4.4%)”“6 (3.8%)”“6 (1.9%)”
Malignancy“0 (0.0%)”“0 (0.0%)”“0 (0.0%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“0 (0.0%)”“0 (0.0%)”“2 (0.6%)”
Non-serious adverse events at a 5% reporting threshold in the posted results
Study limitations
Summary: study limitations
  • Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
  • Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
  • Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
  • Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
  • Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
  • Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
  • Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.